182 related articles for article (PubMed ID: 34275349)
1. The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study.
Ong KL; Wu L; Januszewski AS; O'Connell R; Xu A; Scott RS; Sullivan DR; Rye KA; Li H; Ma RC; Li L; Gebski V; Jenkins AJ; Jia W; Keech AC
Diab Vasc Dis Res; 2021; 18(4):14791641211032547. PubMed ID: 34275349
[TBL] [Abstract][Full Text] [Related]
2. Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes.
Mirea AM; Toonen EJM; van den Munckhof I; Munsterman ID; Tjwa ETTL; Jaeger M; Oosting M; Schraa K; Rutten JHW; van der Graaf M; Riksen NP; de Graaf J; Netea MG; Tack CJ; Chavakis T; Joosten LAB
Mol Med; 2019 May; 25(1):16. PubMed ID: 31046673
[TBL] [Abstract][Full Text] [Related]
3. Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study.
Ong KL; Wu L; Januszewski AS; O'Connell RL; Xu A; Rye KA; Ma RCW; Li H; Jenkins AJ; Jia W; Keech AC;
Diabetes Res Clin Pract; 2020 Nov; 169():108450. PubMed ID: 32949655
[TBL] [Abstract][Full Text] [Related]
4. Increased Neutrophil elastase and proteinase 3 are closely associated with occurrence and severity of stroke and acute myocardial infarction in patients with type 2 diabetes mellitus.
Wang L; Pan J; Sun Y; Zong S; Zhang R; Li Y; Yu Z; Liu J; Zang S
Diabetes Res Clin Pract; 2022 Apr; 186():109853. PubMed ID: 35341779
[TBL] [Abstract][Full Text] [Related]
5. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
[TBL] [Abstract][Full Text] [Related]
6. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
7. The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Ong KL; Januszewski AS; O'Connell R; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Hung WT; Scott RS; Taskinen MR; Keech AC; Rye KA
Diabetologia; 2015 Mar; 58(3):464-73. PubMed ID: 25425220
[TBL] [Abstract][Full Text] [Related]
8. Elevated first-trimester neutrophil elastase and proteinase 3 increase the risk of gestational diabetes mellitus and adverse fetal outcomes.
Wang L; Zhou Z; Xu X; Li Y; Zhang R; Yu Z; Huang X; Zang S; Sun T
Reprod Biol Endocrinol; 2024 Jan; 22(1):2. PubMed ID: 38167145
[TBL] [Abstract][Full Text] [Related]
9. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.
Rajamani K; Colman PG; Li LP; Best JD; Voysey M; D'Emden MC; Laakso M; Baker JR; Keech AC;
Lancet; 2009 May; 373(9677):1780-8. PubMed ID: 19465233
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating GM
Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
[TBL] [Abstract][Full Text] [Related]
11. Summarizing the FIELD study: lessons from a 'negative' trial.
Tsimihodimos V; Mikhailidis DP; Elisaf M
Expert Opin Pharmacother; 2013 Dec; 14(18):2601-10. PubMed ID: 24206060
[TBL] [Abstract][Full Text] [Related]
12. Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study.
Ong KL; Januszewski AS; O'Connell R; Buizen L; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Scott RS; Taskinen MR; Rye KA; Keech AC;
Diabetologia; 2015 Sep; 58(9):2035-44. PubMed ID: 26055067
[TBL] [Abstract][Full Text] [Related]
13. More clinical lessons from the FIELD study.
Fazio S
Cardiovasc Drugs Ther; 2009 Jun; 23(3):235-41. PubMed ID: 19160032
[TBL] [Abstract][Full Text] [Related]
14. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.
Davis TM; Ting R; Best JD; Donoghoe MW; Drury PL; Sullivan DR; Jenkins AJ; O'Connell RL; Whiting MJ; Glasziou PP; Simes RJ; Kesäniemi YA; Gebski VJ; Scott RS; Keech AC;
Diabetologia; 2011 Feb; 54(2):280-90. PubMed ID: 21052978
[TBL] [Abstract][Full Text] [Related]
15. Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy.
Harmer JA; Keech AC; Veillard AS; Skilton MR; Marwick TH; Watts GF; Meredith IT; Celermajer DS;
Atherosclerosis; 2015 Sep; 242(1):295-302. PubMed ID: 26233916
[TBL] [Abstract][Full Text] [Related]
16. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.
Ting RD; Keech AC; Drury PL; Donoghoe MW; Hedley J; Jenkins AJ; Davis TM; Lehto S; Celermajer D; Simes RJ; Rajamani K; Stanton K;
Diabetes Care; 2012 Feb; 35(2):218-25. PubMed ID: 22210576
[TBL] [Abstract][Full Text] [Related]
17. Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Williams KH; Sullivan DR; Nicholson GC; George J; Jenkins AJ; Januszewski AS; Gebski VJ; Manning P; Tan YM; Donoghoe MW; Ehnholm C; Young S; O'Brien R; Buizen L; Twigg SM; Keech AC
Metabolism; 2016 May; 65(5):783-793. PubMed ID: 27085785
[TBL] [Abstract][Full Text] [Related]
18. Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes.
Ong KL; Rye KA; O'Connell R; Jenkins AJ; Brown C; Xu A; Sullivan DR; Barter PJ; Keech AC;
J Clin Endocrinol Metab; 2012 Dec; 97(12):4701-8. PubMed ID: 23144467
[TBL] [Abstract][Full Text] [Related]
19. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
Scott R; Best J; Forder P; Taskinen MR; Simes J; Barter P; Keech A;
Cardiovasc Diabetol; 2005 Aug; 4():13. PubMed ID: 16111499
[TBL] [Abstract][Full Text] [Related]
20. Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes.
Januszewski AS; Chen D; Scott RS; O'Connell RL; Aryal NR; Sullivan DR; Watts GF; Taskinen MR; Barter PJ; Best JD; Simes RJ; Keech AC; Jenkins AJ
Sci Rep; 2021 Sep; 11(1):18708. PubMed ID: 34548531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
